Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference
08. August 2023 10:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a medical technology company that creates blood purification...
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application
17. Mai 2023 07:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, May 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, disclosed today...
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
16. Mai 2023 07:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announces...
Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
11. April 2023 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company focused on the...
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
31. März 2023 09:45 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company that creates blood...
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
15. November 2022 07:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Discloses Trademark Applications to Register ChemoPrep™ and ChemoPure™ for Devices to Enhance Cancer Therapy
13. Oktober 2022 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”
06. Oktober 2022 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
04. Oktober 2022 09:00 ET
|
Sigyn Therapeutics, Inc.
- Independent Directors Bring Expertise in Intellectual Property, Finance, Healthcare Delivery, and More - SAN DIEGO, CA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics,...
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
14. September 2022 09:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address...